Literature DB >> 22322857

Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis.

E Kerr1, C Holohan, K M McLaughlin, J Majkut, S Dolan, K Redmond, J Riley, K McLaughlin, I Stasik, M Crudden, S Van Schaeybroeck, C Fenning, R O'Connor, P Kiely, M Sgobba, D Haigh, P G Johnston, D B Longley.   

Abstract

FLIP is a potential anti-cancer therapeutic target that inhibits apoptosis by blocking caspase 8 activation by death receptors. We report a novel interaction between FLIP and the DNA repair protein Ku70 that regulates FLIP protein stability by inhibiting its polyubiquitination. Furthermore, we found that the histone deacetylase (HDAC) inhibitor Vorinostat (SAHA) enhances the acetylation of Ku70, thereby disrupting the FLIP/Ku70 complex and triggering FLIP polyubiquitination and degradation by the proteasome. Using in vitro and in vivo colorectal cancer models, we further demonstrated that SAHA-induced apoptosis is dependant on FLIP downregulation and caspase 8 activation. In addition, an HDAC6-specific inhibitor Tubacin recapitulated the effects of SAHA, suggesting that HDAC6 is a key regulator of Ku70 acetylation and FLIP protein stability. Thus, HDAC inhibitors with anti-HDAC6 activity act as efficient post-transcriptional suppressors of FLIP expression and may, therefore, effectively act as 'FLIP inhibitors'.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322857      PMCID: PMC3392639          DOI: 10.1038/cdd.2012.8

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  40 in total

Review 1.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

2.  Inhibition of death receptor signals by cellular FLIP.

Authors:  M Irmler; M Thome; M Hahne; P Schneider; K Hofmann; V Steiner; J L Bodmer; M Schröter; K Burns; C Mattmann; D Rimoldi; L E French; J Tschopp
Journal:  Nature       Date:  1997-07-10       Impact factor: 49.962

3.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

Authors:  William Kevin Kelly; Owen A O'Connor; Lee M Krug; Judy H Chiao; Mark Heaney; Tracy Curley; Barbara MacGregore-Cortelli; William Tong; J Paul Secrist; Lawrence Schwartz; Stacy Richardson; Elaina Chu; Semra Olgac; Paul A Marks; Howard Scher; Victoria M Richon
Journal:  J Clin Oncol       Date:  2005-05-16       Impact factor: 44.544

4.  Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.

Authors:  Lalji K Gediya; Aashvini Belosay; Aakanksha Khandelwal; Puranik Purushottamachar; Vincent C O Njar
Journal:  Bioorg Med Chem       Date:  2007-12-08       Impact factor: 3.641

5.  Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Authors:  Wm Kevin Kelly; Victoria M Richon; Owen O'Connor; Tracy Curley; Barbara MacGregor-Curtelli; William Tong; Mark Klang; Lawrence Schwartz; Stacie Richardson; Eddie Rosa; Marija Drobnjak; Carlos Cordon-Cordo; Judy H Chiao; Richard Rifkind; Paul A Marks; Howard Scher
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

6.  Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.

Authors:  Fei Guo; Celia Sigua; Jianguo Tao; Purva Bali; Prince George; Yunqing Li; Sylvie Wittmann; Lynn Moscinski; Peter Atadja; Kapil Bhalla
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

7.  A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.

Authors:  Peter M Wilson; Anthony El-Khoueiry; Syma Iqbal; William Fazzone; Melissa J LaBonte; Susan Groshen; Dongyun Yang; Kathy D Danenberg; Sarah Cole; Margaret Kornacki; Robert D Ladner; Heinz-Josef Lenz
Journal:  Cancer Chemother Pharmacol       Date:  2010-04       Impact factor: 3.333

Review 8.  HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination.

Authors:  C Boyault; K Sadoul; M Pabion; S Khochbin
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

9.  Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells.

Authors:  T R Wilson; M McEwan; K McLaughlin; C Le Clorennec; W L Allen; D A Fennell; P G Johnston; D B Longley
Journal:  Oncogene       Date:  2008-09-29       Impact factor: 9.867

10.  c-FLIP inhibits chemotherapy-induced colorectal cancer cell death.

Authors:  D B Longley; T R Wilson; M McEwan; W L Allen; U McDermott; L Galligan; P G Johnston
Journal:  Oncogene       Date:  2006-02-09       Impact factor: 9.867

View more
  40 in total

1.  HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.

Authors:  Robbie Carson; Basak Celtikci; Patrick G Johnston; Sandra Van Schaeybroeck; Cathy Fenning; Arman Javadi; Nyree Crawford; Lucia Perez Carbonell; Mark Lawler; Daniel B Longley
Journal:  Clin Cancer Res       Date:  2015-03-26       Impact factor: 12.531

Review 2.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

Review 3.  Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.

Authors:  Sabnam Parbin; Swayamsiddha Kar; Arunima Shilpi; Dipta Sengupta; Moonmoon Deb; Sandip Kumar Rath; Samir Kumar Patra
Journal:  J Histochem Cytochem       Date:  2013-09-18       Impact factor: 2.479

Review 4.  Chromatin modifications associated with DNA double-strand breaks repair as potential targets for neurological diseases.

Authors:  Camille Brochier; Brett Langley
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 5.  c-FLIP, a master anti-apoptotic regulator.

Authors:  A R Safa
Journal:  Exp Oncol       Date:  2012-10

6.  Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.

Authors:  Laura Bergadà; Annabel Sorolla; Andree Yeramian; Nuria Eritja; Cristina Mirantes; Xavier Matias-Guiu; Xavier Dolcet
Journal:  Mol Oncol       Date:  2013-03-28       Impact factor: 6.603

Review 7.  Targeting apoptotic caspases in cancer.

Authors:  Ashley Boice; Lisa Bouchier-Hayes
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-02-19       Impact factor: 4.739

Review 8.  Cancer drug resistance: an evolving paradigm.

Authors:  Caitriona Holohan; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 9.  New insights into the link between DNA damage and apoptosis.

Authors:  Daniela De Zio; Valentina Cianfanelli; Francesco Cecconi
Journal:  Antioxid Redox Signal       Date:  2012-11-09       Impact factor: 8.401

10.  The pseudo-caspase FLIP(L) regulates cell fate following p53 activation.

Authors:  Andrea Lees; Alexander J McIntyre; Nyree T Crawford; Fiammetta Falcone; Christopher McCann; Caitriona Holohan; Gerard P Quinn; Jamie Z Roberts; Tamas Sessler; Peter F Gallagher; Gemma M A Gregg; Katherine McAllister; Kirsty M McLaughlin; Wendy L Allen; Laurence J Egan; Aideen E Ryan; Melissa J Labonte-Wilson; Philip D Dunne; Mark Wappett; Vicky M Coyle; Patrick G Johnston; Emma M Kerr; Daniel B Longley; Simon S McDade
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.